BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chavez-tapia NC, Murúa-beltrán Gall S, Ordoñez-vázquez AL, Nuño-lambarri N, Vidal-cevallos P, Uribe M. Understanding the Role of Metabolic Syndrome as a Risk Factor for Hepatocellular Carcinoma. JHC 2022;Volume 9:583-93. [DOI: 10.2147/jhc.s283840] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
Number Citing Articles
1 Ito T, Nguyen MH. Perspectives on the Underlying Etiology of HCC and Its Effects on Treatment Outcomes. J Hepatocell Carcinoma 2023;10:413-28. [PMID: 36926055 DOI: 10.2147/JHC.S347959] [Reference Citation Analysis]
2 Yuan B, Ma J, Wang J, Hao J. The effect of metformin usage on survival outcomes for hepatocellular carcinoma patients with type 2 diabetes mellitus after curative therapy. Front Endocrinol (Lausanne) 2022;13:1060768. [PMID: 36583006 DOI: 10.3389/fendo.2022.1060768] [Reference Citation Analysis]
3 Rusu I, Pirlog R, Chiroi P, Nutu A, Puia VR, Fetti AC, Rusu DR, Berindan-Neagoe I, Al Hajjar N. The Implications of Noncoding RNAs in the Evolution and Progression of Nonalcoholic Fatty Liver Disease (NAFLD)-Related HCC. Int J Mol Sci 2022;23:12370. [PMID: 36293225 DOI: 10.3390/ijms232012370] [Reference Citation Analysis]